PTC/SB/08a (08-03)
Approved for use through 07/31/2006 ONE 0651-0201
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unfers it contains a valid OMS control number.

INFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	
(Not for submission under 37 CFR 1.99)	

Application Number		10649387		
Filing Date		2003-08-27		
First Named Inventor Y. NA		KAYA		
Art Unit		2617		
Examiner Name	BRYA	IN J. FOX		
Attorney Docket Number		FUJIX 20.578		

U.S.PATENTS							Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applican of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6407719		2002-06-18	OHIRA ET AL	_			
	2	6624784		2003-09-23	YAMAGUCH				
If you wis	h to a	dd additional U.S. Pate	ent citatio	n information	please click the	Add button.		Add	
			U.S.P	ATENT APP	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document Pages, Columns, Lines was Relevant Passages or Figures Appear		nt Passages or Relev	
	1								
If you wisl	h to a	dd additional U.S. Pub	lished Ap	plication citat	on information	please click the Ad	d button	Add	
				FOREIGN PA	ATENT DOCU	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Publication	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	00/03456	wo		2000-01-20	NTT MOBILE COMMUNICATION NETWORK, INC.		Corresponds to US Patent 6624784	
	2	2001-24431	JP		2001-01-26	ATR ADAPTIVE COMMUNICATION RES LAB		Corresponds to US Patent 6407719	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10649387		
Filing Date		2003-08-27		
First Named Inventor	Y. NA	KAYA		
Art Unit		2617		
Examiner Name BRYA		NN J. FOX		
Attornov Docket Number		FILIX 20 578		

If you wish	to a	dd add	ditional Foreign Patent Document citation information please click the Add button	Add			
			NON-PATENT LITERATURE DOCUMENTS	Remove			
Examinor initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Тв		
	1						
If you wish to add additional non-patent literature document citation information please click the Add button Add							
			EXAMINER SIGNATURE				
Examiner Signature Date Considered							
			reference considered, whether or not citation is in conformance with MPEP 809, rmance and not considered. Include copy of this form with next communication to				

1 See Kind Codes of USPTO Patent Documents at www.USPTO_GOLV or MEPP 901.04. 2 Enter office that issued the document, by the hor-defer code (WIPO Standard 87.3). 3 for Just purspece plant of comments, the included not the year of the register or the precede the set after intumer of the peart for serior of the Emperor or many precede the set after intumer of the peart for serior of the Serior or many preceded to set after intumer of the peart for serior of the Serior or many of the Serior or many of the Serior of th

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10649387
Filing Date		2003-08-27
First Named Inventor	Y. NA	KAYA
Art Unit		2617
Examiner Name	BRYA	NN J. FOX
Attorney Docket Number		FLUX 20 578

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/3/(40.)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Nathan Wahar

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	form of the signature.							
	Signature	/Nathan Weber/	Date (YYYY-MM-DD)	2007-09-18				

Registration Number

50.958

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Officer, U.S. perpartment of Commence, P. 0. Box 1450, Alexandria, V.3.2311-4450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.